LinkedIn Profile

Access Relmada Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:relmadatherapeutics 2601251 May 31st, 2019 12:00AM Relmada Therapeutics, Inc 370 9.00 Open Pharmaceuticals May 31st, 2019 10:38AM May 31st, 2019 10:38AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Open Analgesic Drug Development, Chronic Pain, Pharmaceutical Development, Opioid Addiction Open 757 Third Ave, 20th Floor New York NY US 10017 Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 17th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 16th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 15th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 14th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 13th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 12th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 11th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 10th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology
private:relmadatherapeutics 2601251 Feb 9th, 2018 12:00AM Relmada Therapeutics, Inc 275 8.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit our website at: www.relmada.com Relmada Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.